Patents Assigned to Regeneron Pharmaceuticals
  • Asparagine feed strategies to improve cell culture performance and mitigate asparagine sequence variants
    Patent number: 12163122
    Abstract: A method for culturing eukaryotic cells for improved cell culture performance is provided. The method generally comprises propagating or maintaining eukaryotic cells in a defined cell culture medium; wherein the defined cell culture medium is supplemented with asparagine in an amount from about 2.6 mM to about 43.2 mM during early fed-batch cell culture and from about 2.6 mM to about 21.6 mM during late fed-batch cell culture; and maintaining said cells in said asparagine supplemented cell culture medium for at least a portion of the early fed-batch cell culture and at least a portion of the late fed-batch cell culture; wherein the performance of the cell culture is improved by the asparagine supplementation, as compared to a similar method with a lower amount of asparagine supplementation in the early and/or late fed-batch cell culture.
    Type: Grant
    Filed: August 27, 2021
    Date of Patent: December 10, 2024
    Assignee: Regeneron Pharmaceuticals, Inc.
    Inventors: Sandra Bennun-Serrano, Shawn M. Lawrence, Amy S. Johnson
  • High affinity human antibodies to human IL-4 receptor
    Patent number: 12162943
    Abstract: The present invention provides nucleic acid molecules that encode antibodies or antigen-binding fragments thereof, which specifically bind human interleukin-4 receptor (IL-4R). Also provided are expression vectors comprising nucleic acid molecule that encode anti-IL-4R antibodies, host cells comprising the expression vectors, and methods of producing anti-IL-4R antibodies or antigen-binding fragments thereof comprising growing the host cells under conditions permitting production of the antibody or fragment, and recovering the antibody or fragment so produced.
    Type: Grant
    Filed: October 6, 2020
    Date of Patent: December 10, 2024
    Assignee: REGENERON PHARMACEUTICALS, INC.
    Inventors: Joel H. Martin, Tammy T. Huang, Jeanette L. Fairhurst, Nicholas J. Papadopoulos, George D. Yancopoulos
  • Piezo type mechanosensitive ion channel component 1 (PIEZO1) variants and uses thereof
    Patent number: 12163192
    Abstract: Methods of treating patients having varicose veins, methods of identifying subjects having an increased risk of developing varicose veins, and methods of diagnosing varicose veins in a human subject, comprising detecting the presence of Piezo Type Mechanosensitive Ion Channel Component 1 (PIEZO1) predicted loss-of-function variant nucleic acid molecules and polypeptides in a biological sample from the patient or subject, are provided herein.
    Type: Grant
    Filed: January 12, 2023
    Date of Patent: December 10, 2024
    Assignee: Regeneron Pharmaceuticals, Inc.
    Inventors: Joshua Backman, Aris Baras
  • Non-human animals having a humanized signal-regulatory protein gene
    Patent number: 12161097
    Abstract: Genetically modified non-human animals and methods and compositions for making and using the same are provided, wherein the genetic modification comprises a humanization of an endogenous signal-regulatory protein gene, in particular a humanization of a SIRP? gene. Genetically modified mice are described, including mice that express a human or humanized SIRP? protein from an endogenous SIRP? locus.
    Type: Grant
    Filed: April 27, 2021
    Date of Patent: December 10, 2024
    Assignee: Regeneron Pharmaceuticals, Inc.
    Inventors: Andrew J. Murphy, O. Gavin Thurston, Bindu Varghese, Cagan Gurer
  • CD20-PD1 BINDING MOLECULES AND METHODS OF USE THEREOF
    Publication number: 20240400687
    Abstract: The present disclosure relates to molecules capable of binding to both CD20 and PD1, as well as nucleic acids encoding such molecules, pharmaceutical compositions comprising such molecules, and methods of use thereof. In certain aspects, disclosed are CD20-PD1 binding molecules comprising at least one CD20 targeting moiety and at least one PD1 agonist moiety, where in certain aspects the PD1 agonist moiety is a PDL1 or PDL2 ectodomain or a PD1 binding portion thereof.
    Type: Application
    Filed: May 10, 2024
    Publication date: December 5, 2024
    Applicant: Regeneron Pharmaceuticals, Inc.
    Inventors: Yang SHEN, Bei WANG, Naga Suhasini AVVARU, Chia-Yang LIN, Andrew J. MURPHY
  • NOVEL IL2 AGONISTS AND METHODS OF USE THEREOF
    Publication number: 20240400632
    Abstract: The present disclosure relates to IL2 agonists with improved therapeutic profiles.
    Type: Application
    Filed: August 19, 2024
    Publication date: December 5, 2024
    Applicant: Regeneron Pharmaceuticals, Inc.
    Inventors: Jiaxi WU, Tong ZHANG, Maria del Pilar MOLINA-PORTELA, Eric SMITH, Chia-Yang LIN, Thomas Craig MEAGHER
  • NON-HUMAN ANIMALS HAVING A HUMANIZED LYMPHOCYTE-ACTIVATION GENE 3
    Publication number: 20240397919
    Abstract: Non-human animals, and methods and compositions for making and using the same, are provided, wherein the non-human animals comprise a humanization of a Lymphocyte activation gene 3 (Lag3). The non-human animals may be described, in some embodiments, as having a genetic modification to an endogenous Lag3 locus so that the non-human animals express a Lag3 polypeptide that includes a human portion and an endogenous portion (e.g., a non-human portion).
    Type: Application
    Filed: August 13, 2024
    Publication date: December 5, 2024
    Applicant: Regeneron Pharmaceuticals, Inc.
    Inventors: Alexander O. Mujica, Elena Burova, Andrew J. Murphy
  • Multimeric protein purity determination
    Patent number: 12158473
    Abstract: Improved capillary zone electrophoresis (CZE), affinity capillary electrophoresis (ACE), and partially filled-ACE (PF-ACE) systems and methods for the detection and quantification of specific molecular entities in a mixture thereof are provided. During manufacturing, heterodimeric bispecific antibodies are often produced along with homodimer species, which can confound quantification of the bispecific antibody. Disclosed are capillary electrophoretic systems and methods of detecting a specific homodimer in the mixture of bispecific heterodimer and homodimers. A ligand capable of binding one of the subunits of the bispecific antibody is contacted with the mixture to form a complex having a reduced electrophoretic mobility, thereby enabling detection of the unbound homodimer.
    Type: Grant
    Filed: November 18, 2019
    Date of Patent: December 3, 2024
    Assignee: Regeneron Pharmaceuticals, Inc.
    Inventors: Kathir Muthusamy, Jiann Kae Luo
  • Method of characterization of visible and/or sub-visible particles in biologics
    Patent number: 12158474
    Abstract: A method for characterizing or quantifying one or more proteins in visible and/or sub-visible particles formed in a sample by detecting the at least one visible or sub-visible particle in the sample, isolating and capturing the at least one visible or sub-visible particle to identify a presence of a protein, and using a mass spectrometer to characterize the protein.
    Type: Grant
    Filed: May 8, 2023
    Date of Patent: December 3, 2024
    Assignee: Regeneron Pharmaceuticals, Inc.
    Inventor: Xiaobin Xu
  • Readily isolated bispecific antibodies with native immunoglobulin format
    Patent number: 12157758
    Abstract: A bispecific antibody format providing ease of isolation is provided, comprising immunoglobulin heavy chain variable domains that are differentially modified in the CH3 domain, wherein the differential modifications are non-immunogenic or substantially non-immunogenic with respect to the CH3 modifications, and at least one of the modifications results in a differential affinity for the bispecific antibody for an affinity reagent such as Protein A, and the bispecific antibody is isolable from a disrupted cell, from medium, or from a mixture of antibodies based on its affinity for Protein A.
    Type: Grant
    Filed: October 7, 2021
    Date of Patent: December 3, 2024
    Assignee: Regeneron Pharmaceuticals, Inc.
    Inventors: Samuel Davis, Eric Smith, Douglas MacDonald, Kara Louise Olson
  • Mitochondrial DNA quality control
    Patent number: 12157916
    Abstract: The present disclosure provides methods of identifying unreliable biological samples that may be mislabeled or contaminated, by determining the heteroplasmy and homoplasmy of mitochondrial DNA present in the biological samples.
    Type: Grant
    Filed: August 6, 2021
    Date of Patent: December 3, 2024
    Assignee: Regeneron Pharmaceuticals, Inc.
    Inventors: Ruoyu Zhang, Wei Keat Lim, Gurinder Atwal
  • Detection and quantification of glycosylated peptides
    Patent number: 12157756
    Abstract: A method of purification and/or separation of glycopeptides and quantitation of same. The method includes contacting a sample comprising glycopeptides to a hydrophilic enrichment substrate under conditions that permit the glycopeptides to bind to the hydrophilic enrichment substrate. The glycopeptides are eluted from the hydrophilic enrichment substrate with an ammonium formate and acetonitrile (ACN) in water solution to create an enriched glycopeptide sample, which may be subjected to analysis to identify specific glycopeptides.
    Type: Grant
    Filed: September 1, 2023
    Date of Patent: December 3, 2024
    Assignee: Regeneron Pharmaceuticals, Inc.
    Inventors: Avraham Z. Rosenberg, Biao Shen
  • Treatment of uveitis with endoplasmic reticulum aminopeptidase 1 (ERAP1) inhibitors
    Patent number: 12157891
    Abstract: The present disclosure provides methods of treating subjects having uveitis, and methods of identifying subjects having an increased risk of developing uveitis.
    Type: Grant
    Filed: October 13, 2022
    Date of Patent: December 3, 2024
    Assignee: Regeneron Pharmaceuticals, Inc.
    Inventors: Sahar Gelfman, Ann Ligocki, Giovanni Coppola, Aris Baras, Arden Moscati, Eli A. Stahl, Carmelo Romano, Santiago Mendez Huergo, Jonathan Weyne, Tave Van Zyl
  • ANTIBODY RESISTANT MODIFIED RECEPTORS TO ENHANCE CELL-BASED THERAPIES
    Publication number: 20240390460
    Abstract: Methods for improving engraftment of donor cells in a subject thereof are provided. Such methods can comprise providing donor cells that have been modified to express a first isoform of a target protein (e.g., interleukin-2 receptor subunit gamma (IL2RG)) that is functionally indistinguishable but immunologically distinguishable from a second isoform of the target protein, administering the donor cells to the subject, and then selectively inhibiting host cells in the subject based on their expression of the second isoform of the target protein, thereby improving engraftment of donor cells in the subject. Also provided are combinations for administration to a subject in need thereof, wherein the combination comprises (1) a population of donor cells modified to express a first isoform of a target protein (e.g., IL2RG) and (2) an antagonist (e.g.
    Type: Application
    Filed: August 9, 2024
    Publication date: November 28, 2024
    Applicant: Regeneron Pharmaceuticals, Inc.
    Inventors: Michael Moore, Casandra Panea, Matthew Sleeman, Andrew J. Murphy, George D. Yancopoulos, Liang Zhang, Annabel Romero Hernández
  • GENETICALLY MODIFIED MOUSE THAT EXPRESSES HUMANIZED PD1 AND PD-L1 PROTEINS
    Publication number: 20240389563
    Abstract: Non-human animals, methods and compositions for making and using the same, are provided, wherein said non-human animals comprise a humanization of a Cluster of Differentiation 274 (CD274) gene. Such non-human animals may be described, in some embodiments, as having a genetic modification to an endogenous CD274 gene so that said non-human animals express a Programmed cell death ligand 1 (PD-L1) polypeptide that includes a human portion and an endogenous portion (e.g., a non-human portion).
    Type: Application
    Filed: August 15, 2024
    Publication date: November 28, 2024
    Applicant: Regeneron Pharmaceuticals, Inc.
    Inventors: Elena Burova, Yajun Tang, Ka-Man Venus Lai, Andrew J. Murphy
  • Human antibodies to ebola virus glycoprotein
    Patent number: 12152067
    Abstract: The present invention provides monoclonal antibodies, or antigen-binding fragments thereof, that bind to Ebola virus glycoproteins, pharmaceutical compositions comprising the antibodies and methods of use. The antibodies of the invention are useful for inhibiting or neutralizing Ebola virus activity, thus providing a means of treating or preventing Ebola virus infection in humans. In some embodiments, the invention provides for use of one or more antibodies that bind to the Ebola virus for preventing viral attachment and/or entry into host cells. The antibodies of the invention may be used prophylactically or therapeutically and may be used alone or in combination with one or more other anti-viral agents or vaccines.
    Type: Grant
    Filed: November 9, 2022
    Date of Patent: November 26, 2024
    Assignee: Regeneron Pharmaceuticals, Inc.
    Inventors: Christos Kyratsous, William Olson, Peter Mason, Neil Stahl
  • Method and chromatography system for determining amount and purity of a multimeric protein
    Patent number: 12152056
    Abstract: The invention relates to a chromatography system and method for assessing amount and/or purity of a multimeric protein in a sample, wherein the chromatography system comprises two different affinity chromatography matrices connected via a switch valve.
    Type: Grant
    Filed: August 16, 2019
    Date of Patent: November 26, 2024
    Assignee: REGENERON PHARMACEUTICALS, INC.
    Inventors: Michael Perrone, Audrey Rodriguez, Andrew Tustian, Hanne Bak
  • Chimeric antigen receptors with BCMA specificity and uses thereof
    Patent number: 12150959
    Abstract: B-cell maturation antigen (BCMA) is expressed on malignant plasma cells. The present invention provides BCMA-specific chimeric antigen receptors and cells expressing such chimeric antigen receptors. In certain embodiments, engineered cells expressing the chimeric antigen receptors of the present invention are capable of inhibiting the growth of tumors expressing BCMA. The engineered cells of the invention are useful for the treatment of diseases and disorders in which an upregulated or induced BCMA-targeted immune response is desired and/or therapeutically beneficial. For example, engineered cells expressing the BCMA-specific chimeric antigen receptors of the invention are useful for the treatment of various cancers, including multiple myeloma.
    Type: Grant
    Filed: July 18, 2019
    Date of Patent: November 26, 2024
    Assignee: Regeneron Pharmaceuticals, Inc.
    Inventors: David DiLillo, Frank Delfino, Kevin Bray, Thomas Craig Meagher, Jessica Kirshner, Olga Sineshchekova
  • Unbiased and high-throughput identification and quantification of host cell protein impurities by automated iterative LC-MS/MS (HCP-AIMS) for therapeutic protein development
    Patent number: 12153053
    Abstract: The present disclosure generally pertains to methods of identifying and quantitating host cell proteins (HCPs) in therapeutic protein development. In particular, the present invention generally pertains to methods of liquid chromatography-tandem mass spectrometry (LC-MS/MS) for unbiased identification and sensitive quantitation of HCPs in therapeutic protein development.
    Type: Grant
    Filed: November 17, 2021
    Date of Patent: November 26, 2024
    Assignee: Regeneron Pharmaceuticals, Inc.
    Inventors: Haibo Qiu, Yu Huang, Mengqi Hu
  • AUTO-INJECTOR AND RELATED METHODS OF USE
    Publication number: 20240382681
    Abstract: The present disclosure generally provides for a method of assembling a medical device, comprising forming a first assembly comprising a main body, a needle mechanism, a sterile connector operatively connected with a portion of the needle mechanism and configured to receive a cartridge. The needle mechanism and the sterile connector form a fluid path assembly which attaches with the main body forming the first assembly. The method further includes forming a second assembly comprising a base end and a translation mechanism, the translation mechanism is configured to engage the cartridge, and combining the first assembly and the second assembly.
    Type: Application
    Filed: May 16, 2024
    Publication date: November 21, 2024
    Applicant: Regeneron Pharmaceuticals, Inc.
    Inventor: Bryan C. GRYGUS